Home / Expertise / Life Sciences & Healthcare

Life Sciences & Healthcare

Spain

CMS Albiñana & Suárez de Lezo provides advice on all aspects affecting the pharmaceutical industry, including domestic and international corporate transactions as well as regulatory, intellectual property and dispute resolution matters relating to product or other forms of liability.

We boast a team of more than 300 lawyers specialising in healthcare and pharmaceutical law with the support of the Lifesciences Asia-Pacific Network (LAN), enabling us to understand the scientific, commercial and legal obligations affecting pharmaceutical companies. We work with the 100 most important pharmaceutical, medical equipment, biotechnology, agriculture and food companies, including 20 pharmaceutical multinationals and nine of the ten biggest medical equipment enterprises.

With active members in key sector associations such as ABPI, ABPI, BIVDA, PAGB, EUCOMED and EFPIA, we contribute to the design of regulatory frameworks affecting the pharmaceutical and healthcare sectors. We advise clients on their daily operational needs, including advertising and promotion, as well as public procurement, price and refund policies, the use of patents, commercial agreements and clinical trials. Moreover, we also provide regulatory advice on complex issues relating to strategic agreements, corporate transactions and legal proceedings for product or other forms of liability.

Read more Read less

Feed

Show only
09 January 2019
CMS among Spain’s most re­cog­nised firms
Iberi­an Law­yer has pub­lished a fea­ture on the most re­cog­nised law firms in Spain, with CMS de­b­ut­ing as one of the rank­ing’s strongest new­comers.  The list has been com­piled based on in­form­a­tion gathered...
20 April 2020
CMS Ex­pert Guide to ad­vert­ising of medi­cines and med­ic­al devices
Ad­vert­ising of phar­ma­ceut­ic­als and med­ic­al devices is a chal­len­ging area for the Life Sci­ences and Health­care in­dustry.The leg­al frame­work is con­stantly chan­ging. Due to very few laws on this area, there...
23 November 2020
EU high court con­firms CBD is not a nar­cot­ic
In a long-awaited rul­ing, the European Court of Justice (ECJ) cla­ri­fied that the can­nabis act­ive in­gredi­ent Can­na­bi­d­i­ol (CBD) is not to be clas­si­fied as a nar­cot­ic. France sub­mits ques­tion on CBD in e-ci­gar­ettes...
18 October 2017
Blanca Es­cribano on di­git­al health
The In­ter­na­tion­al Bar As­so­ci­ation | Oc­to­ber 2017
20 April 2020
CMS Ex­pert Guide to can­nabis law and le­gis­la­tion
In re­cent years can­nabis trade and re­lated activ­ity has de­veloped in­to a growth busi­ness area. In the life sci­ences and health­care fields there have been in­creases in the num­bers of pa­tients hav­ing ac­cess...
16 November 2020
Schrems II re­vis­ited: the European data au­thor­ity pub­lishes draft guid­ance...
On 11 Novem­ber 2020, the European Data Pro­tec­tion Board (EDPB) pub­lished two re­com­mend­a­tions that provide guid­ance to com­pan­ies on how to as­sess data trans­fers after the ECJ’s Schrems II de­cision:...
30/03/2012
Alert Reg­u­lated Sec­tors March 2012 - Brief memo on Span­ish Roy­al De­cree...
29 October 2020
EU Gen­er­al Court cla­ri­fies in­ter­pret­a­tion of “sat­is­fact­ory meth­od” in the...
In the re­cent case of Me­dac Gesell­schaft für klin­is­che Spezi­al­prä­par­ate mbH v European Com­mis­sion, the EU Gen­er­al Court has an­nulled a de­cision of the European Com­mis­sion in which it held that the ap­plic­ant’s...
13/12/2011
Alert Reg­u­lated Sec­tors Decem­ber 2011 - Ef­fects of Su­preme Court Judge­ment...
28 October 2020
New EPO Guidelines ex­pec­ted re­gard­ing amend­ing a de­scrip­tion: what’s all...
Sum­mary The EPO re­quire­ment to amend the de­scrip­tion to con­form with al­lowed claims is chan­ging sig­ni­fic­antly. Ex­am­iners have already been giv­en in­tern­al guid­ance and re­vi­sions to the EPO Guidelines...
08/07/2011
Pub­lic Law Alert Ju­ly 2011
08 October 2020
Ger­many tries again to rat­i­fy Uni­fied Pat­ent Court-Agree­ment
A bill for ap­prov­al of the Agree­ment on the Uni­fied Pat­ent Court (UPCA), le­gis­la­tion that would al­low Ger­many to rat­i­fy this con­ven­tion and to par­ti­cip­ate in this in­ter­na­tion­al pat­ent court sys­tem, was...